Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct;22(10):1421-1422.
doi: 10.1016/S1473-3099(22)00524-2. Epub 2022 Sep 1.

Evasion of neutralising antibodies by omicron sublineage BA.2.75

Affiliations

Evasion of neutralising antibodies by omicron sublineage BA.2.75

Daniel J Sheward et al. Lancet Infect Dis. 2022 Oct.
No abstract available

PubMed Disclaimer

Conflict of interest statement

STR is a cofounder of, and held shares in, deepCDR Biologics, which has been acquired by Alloy Therapeutics. DJS, GBKH, and BM have intellectual property rights associated with antibodies that neutralise omicron variants. All other authors declare no competing interests.

Figures

Figure
Figure
Evasion of neutralising antibodies by BA.2.75 (A) Neutralising 50% inhibitory concentration (IC50) titres (ng/μl) for monoclonal antibodies against ancestral B.1 (D614G) and omicron sublineages BA.2, BA.5, and BA.2.75 in a pseudovirus neutralisation assay. (B) Neutralisation of BA.2.75 relative to BA.2, BA.5, and B.1 by serum (n=20) from blood donated Nov 8–14, 2021, in Stockholm, Sweden, before a wave of infections dominated by BA.1 and BA.2 (left-hand chart). Neutralisation by serum (n=20) donated April 11–17, 2022, after the infection wave (right-hand chart). Values shown above the charts in (B) are the geometric mean ID50 titres. Serum with an ID50 less than the lowest dilution tested (20, dotted line) is plotted as 20. ID50=50% inhibitory dilution.

References

    1. Cao Y, Yisimayi A, Jian F, et al. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by omicron infection. Nature. 2022 doi: 10.1038/S41586-022-04980-y. published online June 17. - DOI - PMC - PubMed
    1. Qu P, Faraone J, Evans JP, et al. Neutralization of the SARS-CoV-2 omicron BA.4/5 and BA.2.12.1 subvariants. N Engl J Med. 2022;386:2526–2528. - PMC - PubMed
    1. Arora P, Kempf A, Nehlmeier I, et al. Augmented neutralisation resistance of emerging omicron subvariants BA.2.12.1, BA.4, and BA.5. Lancet Infect Dis. 2022;22:1117–1118. - PMC - PubMed
    1. Yamasoba D, Kosugi Y, Kimura I, et al. Neutralisation sensitivity of SARS-CoV-2 omicron subvariants to therapeutic monoclonal antibodies. Lancet Infect Dis. 2022;22:942–943. - PMC - PubMed
    1. Greaney AJ, Starr TN, Bloom JD. An antibody-escape estimator for mutations to the SARS-CoV-2 receptor-binding domain. Virus Evol. 2022;8 - PMC - PubMed